New Reduced-Intensity Conditioning for HSCT Found Beneficial for 20 Rare Diseases

A recent study published in the journal Blood Advances has documented that hematopoietic stem cell transplantation (HSCT) is both safe and effective for children with many different kinds of inherited nonmalignant conditions…

Continue Reading New Reduced-Intensity Conditioning for HSCT Found Beneficial for 20 Rare Diseases
First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma
cocoparisienne / Pixabay

First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma

  Recently, clinical-stage biopharmaceutical company Aura Biosciences announced a Phase 2 clinical trial to determine the safety, efficacy, and tolerability of AU-011 for patients with choroidal melanoma. Currently, Aura Biosciences…

Continue Reading First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma
September 21-25 is Global ITP Awareness Week: Spreading Rare Disease Awareness
source: pixabay.com

September 21-25 is Global ITP Awareness Week: Spreading Rare Disease Awareness

In 2020, September 21-25 will be recognized as Global Immune Thrombocytopenia (ITP) Awareness Week. The week will aim to help spread awareness about ITP around the world both in the…

Continue Reading September 21-25 is Global ITP Awareness Week: Spreading Rare Disease Awareness
FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug
source: pixabay.com

FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug

According to a story from globenewswire.com, the US Food and Drug Administration (FDA) recently accepted the New Drug Application (NDA) for arimoclomol. This application is for the use of the…

Continue Reading FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug